Clinical Report: Complete Response to Targeted RAF/MEK Inhibition in Wilms Tumor
Overview
Revise to include initial treatment details and context of the BRAF V600E mutation.
Background
Wilms tumor is the most prevalent renal malignancy in children, with standard treatments yielding high survival rates for most patients. However, relapsed cases often have poor outcomes and limited treatment options. This case underscores the potential of precision-targeted therapies in improving survival for patients with recurrent Wilms tumor.
Data Highlights
No numerical data available in the source material.
Key Findings
The patient achieved a sustained complete remission after BRAF/MEK inhibition.
He remains disease-free for two years following the cessation of targeted therapy.
This case represents the first report of long-term survival after targeted therapy for multiply relapsed Wilms tumor.
Genomic profiling identified the BRAF V600E mutation as a target for therapy.
The treatment regimen was well tolerated without major adverse events.
Clinical Implications
This case highlights the importance of molecular profiling in guiding treatment decisions for relapsed Wilms tumor. The successful use of BRAF/MEK inhibitors may offer a new therapeutic avenue for patients with similar genetic profiles.
Conclusion
The long-term disease-free status of this patient following targeted therapy illustrates the potential for precision medicine in managing challenging cases of Wilms tumor. Further studies are warranted to explore the broader applicability of these findings.
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...
